Phase 2Active, not recruiting
Effect of Rapamycin in Ovarian Aging
- Sponsor
- Columbia University (Academic or other)
- Enrolment
- 50 enrolled
- Conditions
- Perimenopausal
- Interventions
- Rapamycin; Placebo
- Ages
- adults
- Registry
- NCT05836025
From the registry
The investigators are proposing a prospective, randomized, double-blind, placebo-controlled pilot study assessing the ability of low-dose rapamycin to delay ovarian aging in women. Animal studies have shown the potential of rapamycin in slowing or reversing some age-associated pathways.
Primary outcomes
- Measure of Ovarian Reserve